Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatotoxicity with combination of vemurafenib and ipilimumab.

× No keyword cloud information.

263 in total

1. A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.

Authors: Alexander K Tsai; Asra Y Khan; Christina E Worgo; Lucy L Wang; Yuanyuan Liang; Eduardo Davila
Journal: Cancer Immunol Res Date: 2017-08-03 Impact factor: 11.151

Review 2. Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors: Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal: Cancer Discov Date: 2014-11-13 Impact factor: 39.397

Review 3. New treatments for metastatic melanoma.

Authors: Craig Gedye; David Hogg; Marcus Butler; Anthony M Joshua
Journal: CMAJ Date: 2014-02-18 Impact factor: 8.262

4. New combinations and immunotherapies for melanoma: latest evidence and clinical utility.

Authors: Alexander M Menzies; Georgina V Long
Journal: Ther Adv Med Oncol Date: 2013-09 Impact factor: 8.168

5. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

Authors: Christine E Engeland; Christian Grossardt; Rūta Veinalde; Sascha Bossow; Diana Lutz; Johanna K Kaufmann; Ivan Shevchenko; Viktor Umansky; Dirk M Nettelbeck; Wilko Weichert; Dirk Jäger; Christof von Kalle; Guy Ungerechts
Journal: Mol Ther Date: 2014-08-26 Impact factor: 11.454

6. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

Authors: Ester Simeone; Antonio Maria Grimaldi; Lucia Festino; Diana Giannarelli; Vito Vanella; Marco Palla; Marcello Curvietto; Assunta Esposito; Giuseppe Palmieri; Nicola Mozzillo; Paolo Antonio Ascierto
Journal: Oncoimmunology Date: 2017-01-19 Impact factor: 8.110

Hepatotoxicity with combination of vemurafenib and ipilimumab.

1. A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies.

Review 2. Universes collide: combining immunotherapy with targeted therapy for cancer.

Review 3. New treatments for metastatic melanoma.

4. New combinations and immunotherapies for melanoma: latest evidence and clinical utility.

5. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

6. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

7. Melanoma: more answers, more questions.

8. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.

Review 9. Toxicities of Immunotherapy for the Practitioner.

Review 10. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.